Prevalence and long-term monitoring of humoral immunity against adeno-associated virus in Duchenne Muscular Dystrophy patients
- PMID: 29571923
- DOI: 10.1016/j.cellimm.2018.03.004
Prevalence and long-term monitoring of humoral immunity against adeno-associated virus in Duchenne Muscular Dystrophy patients
Abstract
Adeno-associated virus (AAV) vectors are promising candidates for gene therapy and have been explored as gene delivery vehicles in the treatment of Duchenne Muscular Dystrophy (DMD). Recent studies showed compelling evidence of therapeutic efficacy in large animal models following the intravenous delivery of AAV vectors expressing truncated forms of dystrophin. However, to translate these results to humans, careful assessment of the prevalence of anti-AAV neutralizing antibodies (NAbs) is needed, as presence of preexisting NABs to AAV in serum have been associated with a drastic diminution of vector transduction. Here we measured binding and neutralizing antibodies against AAV serotype 1, 2, and 8 in serum from children and young adults with DMD (n = 130). Results were compared with to age-matched healthy donors (HD, n = 113). Overall, approximately 54% of all subjects included in the study presented IgG to AAV2, 49% to AAV1, and 41% to AAV8. A mean of around 80% of IgG positive sera showed neutralizing activity with no statistical difference between DMD and HD. NAb titers for AAV2 were higher than AAV1, and AAV8 in both populations studied. Older DMD patients (13-24 years old) presented significantly lower anti-AAV8 IgG4 subclass. Anti-AAV antibodies were found to be decreased in DMD patients subjected to a 6-month course of corticosteroids and in subjects receiving a variety of immunosuppressive drugs including B cell targeting drugs. Longitudinal follow up of humoral responses to AAV over up to 6 years showed no change in antibody titers, suggesting that in this patient population, seroconversion is a rare event in humans.
Keywords: AAV humoral immunity; Duchenne Muscular Dystrophy; Gene therapy.
Copyright © 2018 Elsevier Inc. All rights reserved.
Similar articles
-
Seroprevalence of Adeno-Associated Virus Neutralizing Antibodies in Males with Duchenne Muscular Dystrophy.Hum Gene Ther. 2023 May;34(9-10):430-438. doi: 10.1089/hum.2022.081. Epub 2022 Dec 19. Hum Gene Ther. 2023. PMID: 36324212 Free PMC article.
-
Therapeutic Application of Extracellular Vesicles-Capsulated Adeno-Associated Virus Vector via nSMase2/Smpd3, Satellite, and Immune Cells in Duchenne Muscular Dystrophy.Int J Mol Sci. 2022 Jan 28;23(3):1551. doi: 10.3390/ijms23031551. Int J Mol Sci. 2022. PMID: 35163475 Free PMC article. Review.
-
Pre-existing antibodies to candidate gene therapy vectors (adeno-associated vector serotypes) in domestic cats.PLoS One. 2019 Mar 21;14(3):e0212811. doi: 10.1371/journal.pone.0212811. eCollection 2019. PLoS One. 2019. PMID: 30897117 Free PMC article.
-
Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy.Hum Gene Ther Methods. 2013 Apr;24(2):59-67. doi: 10.1089/hgtb.2012.243. Epub 2013 Apr 3. Hum Gene Ther Methods. 2013. PMID: 23442094 Free PMC article. Review.
-
Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia.Gene Ther. 2012 Mar;19(3):288-94. doi: 10.1038/gt.2011.90. Epub 2011 Jun 23. Gene Ther. 2012. PMID: 21697954
Cited by
-
Multicenter assessment and longitudinal study of the prevalence of antibodies and related adaptive immune responses to AAV in adult males with hemophilia.Gene Ther. 2024 May;31(5-6):273-284. doi: 10.1038/s41434-024-00441-5. Epub 2024 Feb 14. Gene Ther. 2024. PMID: 38355967 Free PMC article.
-
Understanding AAV vector immunogenicity: from particle to patient.Theranostics. 2024 Jan 20;14(3):1260-1288. doi: 10.7150/thno.89380. eCollection 2024. Theranostics. 2024. PMID: 38323309 Free PMC article. Review.
-
Comparison of Pre-existing Anti-AAV8 Total Antibody Screening and Confirmatory Assays with a Cell-Based Neutralizing Assay in Normal Human Serum.AAPS J. 2023 Apr 3;25(3):35. doi: 10.1208/s12248-023-00805-6. AAPS J. 2023. PMID: 37012501
-
Prevalence of Neutralizing Antibodies against Adeno-Associated Virus Serotypes 1, 2, and 9 in Non-Injected Latin American Patients with Heart Failure-ANVIAS Study.Int J Mol Sci. 2023 Mar 14;24(6):5579. doi: 10.3390/ijms24065579. Int J Mol Sci. 2023. PMID: 36982654 Free PMC article.
-
Binding and neutralizing anti-AAV antibodies: Detection and implications for rAAV-mediated gene therapy.Mol Ther. 2023 Mar 1;31(3):616-630. doi: 10.1016/j.ymthe.2023.01.010. Epub 2023 Jan 11. Mol Ther. 2023. PMID: 36635967 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical